Comparative evaluation of the efficacy of an incomplete cytoreduction application in combination with systemic therapy and systemic therapy as mono-therapy in patients with metastatic clear-cell renal cell carcinomas
- Authors: Borisov PS1, Orlova RV1,2,3, Shkolnik MI4, Karlov PA1
-
Affiliations:
- Saint Petersburg City Oncology Clinic
- Saint Petersburg State University
- L.G.Sokolov Clinical Hospital №122
- Russian Scientific Center of Radiology and Surgical Technologies
- Issue: Vol 17, No 4 (2015)
- Pages: 26-33
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27018
- ID: 27018
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
P S Borisov
Saint Petersburg City Oncology Clinicзам. глав. врача по организационно-методической работе СПб ГБУЗ ГКОД 197022, Russian Federation, Saint Petersburg, 2-ia Berezovaia alleia, d. 3/5
R V Orlova
Saint Petersburg City Oncology Clinic; Saint Petersburg State University; L.G.Sokolov Clinical Hospital №122д-р мед. наук, проф., зав. каф. онкологии медицинского фак-та ФГБОУ ВПО СПбГУ, вед. специалист СПб ГБУЗ ГКОД, рук. специализированного центра онкологии, главный онколог ФГБУЗ КБ №122 им. Л.Г.Соколова 199034, Russian Federation, Saint Petersburg, Universitetskaia nab. d. 7/9
M I Shkolnik
Russian Scientific Center of Radiology and Surgical Technologiesд-р мед. наук, рук. отд-ния оперативной урологии, вед. науч. сотр. ФГБУ РНЦРХТ 197758, Russian Federation, Saint Petersburg, pos. Pesochnyi,Leningradskaia ul., d. 70
P A Karlov
Saint Petersburg City Oncology Clinicзав. онкоурологическим отд-нием СПб ГБУЗ ГКОД 197022, Russian Federation, Saint Petersburg, 2-ia Berezovaia alleia, d. 3/5
References
- Матвеев В.Б., Волкова М.И. Последовательная терапия при диссеминированном раке почки. Онкоурология. 2013; 1: 28-33.
- Motzer R.J, Hutson T.E, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal - cell carcinoma. N Engl J Med 2007; 356 (2): 115-24.
- Escudier B, Pluzanska A, Koralewski P et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double - blind phase III trial. Lancet 2007; 370 (9605): 2103-11.
- Rini B.I, Halabi S, Rosenberg J.E et al. Bevacizumab plus interferon alfa compared with interferon alfamonotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-8.
- Escudier B, Szczylik C, Eisen T et al. Randomized III phase of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract LBA4510]. Proc Am Soc Clin Oncol 2005; 23.
- Sternberg C.N, Davis I.D, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28 (6): 1061-8.
- Hudes G, Carducci M, Tomczak P et al. Temsirolimus, Interferon alfa, or Both for Advanced Renal-Cell Carcinoma. N Engl J Med 2007; 356 (22): 2271-81.
- Rini B.I, Escudier B, Tomczak P. Axitinib versus Sorafenib as second - line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. J Clin Oncol 2011; 29 (Suppl.; abstr. 4503).
- Motzer R.J, Escudier B.J, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double - blind, randomized, placebocontrolled phase III trial. Lancet 2008; 372 (9637): 449-56.
- Ljunberg B et al. Guidelines on Renal Cell Carcinoma. Eur Ass Urol 2015; p. 36-9.
- Di Lorenzo G, Buonerba C, Federico P et al. Third Line Sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic. Renal Cell Carc 2010; 58: 62.
- Gruenwald V, Seidel C, Fenner M. Antitumor activity of tyrosine kinase inhibitors (TKI) after failure of RAD001 in metastatic renal cell carcinoma (mRCC). Abstr. 414. Available at: http://www.asco.org/acov2/Meetings/Abstracts
- Alt A.L, Boorjian S.A, Lohse C.M et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011; 117 (13): 2873-8.
- Kwak C, Park Y.H, Jeong C.W et al. Metastasectomy without systemic therapy in metastatic renal cell carcinoma: Comparison with conservative treatment. Urol Int 2007; 79 (2): 145-51.
- Lee S.E, Kwak C, Byun S.S et al. Metastatectomy prior to immunochemotherapy for metastatic renal cell Carcinoma. Urol Int 2006; 76 (3): 256-63.
- Petralia G, Roscigno M, Zigeuner R et al. Complete metastasectomy is an independent predictor of cancerspecific survival in patients with clinically metastatic renal cell carcinoma. Eur Urol Suppl 2010; 9: 162.
- Staehler M, Kruse J, Haseke N et al. Metastasectomy significantly prolongs survival in patients with metastatic renal cancer. Eur Urol Suppl 2009; 8: 18.
- Eggener S.E, Yossepowitch O, Kundu S et al. Risk score and metastasectomy independently impact prognosisof patients with recurrent renal cell carcinoma. J Urol 2008; 180: 873-8.
- Давыдов М.И., Матвеев В.Б., Полоцкий Б.Е. и др. Хирургическое лечение метастазов рака почки в легких. Рос. онкол. журн. 2003; 4: 15-9.
- Kavolius J.P, Mastorakos D.P, Pavlovich C et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998; 16: 2261-6.
- Fuchs B et al. Clinical Orthop Relat Res 2005; 431: 187-92.
- Кострицкий С.В., Широкорад В.И., Семенов Д.В. и др. Хирургическое лечение метастазов рака почки в длинные трубчатые кости. Онкоурология. 2013; 2: 18-20.